By Suherman Candra Maholtra 
In a significant advancement for the fields of synthetic biology and infectious disease, a research team at the University of Cincinnati has successfully demonstrated that specially engineered probiotic bacteria can serve as a sophisticated oral delivery system for both antiviral vaccines and therapeutic agents. The study, led by Nalinikanth Kotagiri, PhD, and published in the peer-reviewed journal Gut Microbes, details a "plug-and-play" platform that utilizes the common bacterium E. coli Nissle 1917 to transport medical payloads directly to the gastrointestinal tract. By leveraging the natural mechanisms of the gut, this technology offers a potential solution to some of the most persistent challenges in global health, including the need for needle-free administration and the elimination of complex cold-chain logistics required for traditional vaccines.
The Scientific Foundation: Engineering the Microbial Chassis
The core of this breakthrough lies in the manipulation of E. coli Nissle 1917, a non-pathogenic bacterial strain that has been used safely as a probiotic for over a century. Unlike many pathogenic strains of E. coli, Nissle 1917 is known for its ability to colonize the human gut without causing disease, often providing protective benefits against intestinal pathogens. Dr. Kotagiri’s lab at the University of Cincinnati’s James L. Winkle College of Pharmacy has spent years repurposing this "chassis" for various medical applications, ranging from the degradation of tumor defenses to the diagnostic imaging of pulmonary infections.
The team’s most recent endeavor focused on whether this bacterial vehicle could be adapted to fight viral infections. Using SARS-CoV-2, the virus responsible for COVID-19, as a proof-of-concept, the researchers engineered the bacteria to produce and display specific viral proteins. The innovation lies in the bacterial secretion system; while most engineered microbes retain their therapeutic cargo within their cell walls, Kotagiri’s team designed the bacteria to export their payload. This was achieved by harnessing outer-membrane vesicles (OMVs)—microscopic, spherical structures that bacteria naturally shed. These OMVs act as biological "postmasters," packaging the engineered antigens or therapeutic nanobodies and ferrying them across the gut epithelium into the bloodstream and distant tissues.
A New Frontier in Immunity: Targeting the Mucosal Gateway
One of the primary motivations for developing an oral delivery system is the pursuit of "mucosal immunity." Most current vaccines, including the widely used mRNA COVID-19 shots, are administered via intramuscular injection. While these are highly effective at generating systemic immunity—circulating antibodies (IgG) in the blood that prevent severe disease—they are often less efficient at preventing the initial infection at the site of entry.
Viruses like SARS-CoV-2, influenza, and norovirus typically enter the body through mucosal surfaces, such as the lining of the lungs, nose, and gastrointestinal tract. To block infection at these "gateways," the body requires secretory immunoglobulin A (IgA). The University of Cincinnati study found that their oral bacterial platform was uniquely capable of stimulating high levels of IgA in both the gut and the airways of preclinical models.
"Oral delivery lets us target the mucosal surfaces where pathogens first gain a foothold while avoiding needles and cold-chain logistics," explained Dr. Kotagiri. The data from the study indicated that a two-dose oral regimen of the engineered bacteria produced systemic antibody levels comparable to those achieved by traditional mRNA vaccines, but with the added benefit of significantly superior mucosal protection. This suggests that the platform could not only prevent severe illness but potentially reduce viral transmission by stopping the virus before it takes root.
Advanced Therapeutics: The Role of Nanobodies
Beyond its application as a vaccine platform, the research team developed a version of the bacteria intended for post-exposure therapy. This involves the delivery of monoclonal antibodies—specifically, nanobodies. Nanobodies are a specialized class of antibody fragments that are approximately one-tenth the size of conventional antibodies. Their small size allows them to penetrate tissues more effectively and bind to viral structures that might be inaccessible to larger molecules.
In the UC study, the engineered E. coli Nissle 1917 was programmed to display and release anti-spike nanobodies. Once ingested, the bacteria colonized the gut and began a continuous production cycle, releasing nanobodies into the host’s system via OMVs. The researchers found that these nanobodies accumulated in the lung tissue, where they successfully neutralized SARS-CoV-2 in ex-vivo assays.
Nitin S. Kamble, PhD, a research scientist in Kotagiri’s lab and a lead contributor to the study, highlighted the efficiency of this method. "A unique aspect of this approach is the use of OMVs as natural postmasters, efficiently packaging and delivering these therapeutic molecules to their intended targets," Kamble stated. He noted that because the probiotic can remain in the gut for several days or even weeks, it creates a "self-renewing and sustained depot" of antiviral molecules, potentially replacing the need for repeated intravenous infusions of monoclonal antibodies.
Chronology of Development and Preclinical Success
The development of this platform followed a rigorous multi-year timeline. The project began several years ago when the team first hypothesized that the gut-lung axis could be exploited for viral defense. The initial phase involved the systematic screening of anchor motifs and expression cassettes to ensure that the viral antigens were displayed on the bacterial surface at a high enough density to trigger an immune response.
Following the optimization of the bacterial construct, the team moved into preclinical animal models. The chronology of the research highlights several key milestones:
- Optimization Phase: The researchers tested various genetic "plugs" to ensure the bacteria could reliably produce the SARS-CoV-2 spike protein.
- Administration Phase: Animal models were given a two-dose oral regimen, mimicking a standard vaccination schedule.
- Observation Phase: The team monitored the distribution of OMVs and the subsequent production of antibodies over several weeks.
- Neutralization Phase: Ex-vivo assays were conducted to confirm that the antibodies and nanobodies produced were capable of neutralizing the actual virus.
The results were consistent: the engineered bacteria were safe, did not cause adverse immune reactions or side effects in the animal models, and provided robust protection.
Global Health Implications and Logistical Advantages
The implications of an oral, probiotic-based vaccine extend far beyond the laboratory. One of the greatest hurdles in global immunization efforts is the "cold chain"—the requirement that vaccines be kept at extremely low temperatures from the point of manufacture to the point of administration. mRNA vaccines, for instance, often require ultra-cold storage, which is difficult to maintain in developing nations or rural areas with limited infrastructure.
Because E. coli Nissle 1917 is a hardy bacterium that can be lyophilized (freeze-dried) into a stable powder or pill form, it could theoretically be shipped and stored at room temperature. This would drastically reduce the cost and complexity of vaccination campaigns. Furthermore, the removal of needles eliminates the risks associated with needle reuse and disposal, while also increasing public compliance among those with needle phobia.
From a public health perspective, the "plug-and-play" nature of the platform is perhaps its most promising feature. Now that the delivery mechanism has been validated, the genetic sequence for the SARS-CoV-2 spike protein can be swapped out for antigens from other viruses. Dr. Kotagiri has already identified influenza and norovirus as the next targets for the platform.
Future Outlook and Clinical Integration
While the results are promising, the transition from animal models to human clinical trials remains the next critical step. These trials will be essential to validate the safety and efficacy of the platform in humans, particularly regarding how long the engineered bacteria can persist in the human microbiome and whether they might be outcompeted by native gut flora.
However, the team remains optimistic given the long safety record of the parent bacterial strain. "In the future, maybe we can integrate both agents so the same bacteria has both the vaccine and the nanobody therapy components," Kotagiri said. This dual-action approach could provide a "one-stop shop" for viral defense, offering immediate therapeutic protection alongside long-term immunological priming.
The research was supported by significant grants from the National Institutes of Health (NIH) and the Congressionally Directed Medical Research Programs (CDMRP). As the University of Cincinnati team moves forward with patent applications and further testing, their work stands as a testament to the power of synthetic biology to transform traditional medicine into a more accessible, efficient, and resilient system for the 21st century.
The study’s coauthors include Shindu Thomas, Tushar Madaan, Nadia Ehsani, Saqib Sange, Kiersten Tucker, Alexis Muhumure, and Sarah Kunkler. Their collective work marks a pivotal moment in the evolution of oral biologics, potentially shifting the paradigm of how the world prepares for and responds to future viral outbreaks.